Form 4: Akero COO Sells Shares for Tax Obligations

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 586 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (AKRO), reported a transaction on September 11, 2025.
• He sold 586 shares of Akero Therapeutics common stock at a price of $43.02 per share.
• The sale was an automatic "sell-to-cover" transaction, executed to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• Following this transaction, Jonathan Young directly beneficially owns 196,898 shares of common stock.
• Additionally, 60,000 shares are held indirectly in three irrevocable trusts for the benefit of his children, for which he disclaims beneficial ownership.

Sentiment

Score: 6

Explanation: The sale was an automatic 'sell-to-cover' transaction for tax withholding obligations, not a discretionary sale, which mitigates negative sentiment typically associated with insider selling, making it a neutral to slightly positive event.

Positives

• The sale was not discretionary but an automatic "sell-to-cover" transaction for tax purposes, indicating no voluntary divestment based on personal outlook or company performance concerns.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if for tax purposes, reduces their direct equity stake in the company.

Future Outlook

NA

Management Comments

• The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person.
• Such sales were automatic and not at the discretion of the Reporting Person.
• The Reporting Person disclaims beneficial ownership of these securities [in trusts], and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Corporate Governance

Related Party Transactions

• Shares are held in irrevocable trusts for the benefit of the Reporting Person's children, with the Reporting Person's spouse serving as trustee.

Stakeholder Impact

• Shareholders: The non-discretionary nature of the sale limits negative signaling that might otherwise arise from an insider selling shares.
• Employees: Reinforces standard practices for equity compensation and tax compliance within the company.

Key Dates

Recommendation

The transaction is a non-discretionary 'sell-to-cover' for tax withholding obligations related to restricted stock unit vesting. This is a common and expected event for executives and does not reflect a change in the executive's outlook on the company's prospects. Therefore, it does not provide a basis for altering an existing investment thesis.

Keywords

Akero Therapeutics, AKRO, Jonathan Young, Chief Operating Officer, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding